Karl Storz Endoscopy-America Inc v. STERIS Instrument Management Services, Inc.

CourtDistrict Court, N.D. Alabama
DecidedMarch 12, 2020
Docket2:12-cv-02716
StatusUnknown

This text of Karl Storz Endoscopy-America Inc v. STERIS Instrument Management Services, Inc. (Karl Storz Endoscopy-America Inc v. STERIS Instrument Management Services, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Karl Storz Endoscopy-America Inc v. STERIS Instrument Management Services, Inc., (N.D. Ala. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ALABAMA SOUTHERN DIVISION ____________________________________ KARL STORZ ENDOSCOPY- ) AMERICA INC., ) ) Plaintiff, ) ) Civil Action No. 2:12-cv-02716-KOB v. ) ) INTEGRATED MEDICAL SYSTEMS ) INTERNATIONAL, INC., ) ) Defendant. ) )

MEMORANDUM OPINION This matter comes before the court on the parties’ proposed claim constructions regarding disputed terms in two United States patents. In its third amended complaint, Plaintiff Karl Storz Endoscopy-America Inc. (“KSEA”) alleges that Defendant Integrated Medical Systems International, Inc. (“IMS”) has infringed on U.S. Patent No. 7,530,945 (the ‘945 patent) and U.S. Reissued Patent No. RE47,044 (the ‘044 patent). (Doc. 93 at 8, 10). Defendant IMS not only denies wrongdoing, but also has filed a counterclaim alleging noninfringement and invalidity of the same two patents. (Doc. 94). The parties now ask the court to construe disputed claim terms in patents ‘945 and ‘044. The court conducted a Markman1 hearing on February 10, 2020 regarding patent claims in the two patents at issue. After consideration of the parties’ written

and oral arguments regarding the disputed claims, the court has construed the term “transparent” and claims 15 and 23 of the ‘044 patent; however, the court finds construction of the other contested claims unnecessary.

I. Factual Background The two patents at issue in this case concern endoscopes. The parties have agreed that an endoscope is “an instrument that can be at least partially inserted into a cavity to visually examine that cavity.” (Doc. 104 at 2). As described in the

patents at issue here, endoscopes have a tubular shaft containing “a succession of different optical components”—including, for instance, lenses and spacers—that make up an optical system that allows the person operating the endoscope to obtain

a visual image of the cavity into which the endoscope is inserted. (Doc. 93-1 at 7, 93-2 at 7). To obtain good image quality, the interior components of the endoscope must be precisely aligned and fixed into position. For example, there must not be

any gaps between the lenses and the spacers. Assuring correct alignment and image quality requires testing the position of the component parts and the overall performance of the optical system. In many endoscopes, like the prior art

1 Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). endoscopes distinguished by the patents in this case, this quality check cannot be made until after the complete assembly of the endoscope. When a quality check

cannot be performed until after the endoscope is assembled, correction of any errors often becomes expensive because it requires the dismantling of the endoscope.

In the ‘945 patent (a method patent covering the assembly of endoscopes) and the ‘044 patent (a machine patent covering the endoscopes themselves), which are part of the same patent family and are substantially similar, Plaintiff KSEA lays claim to the process of creating an endoscope with an interior tube of

transparent shrinkable material that encloses and fixes the optical components of the endoscope and also allows a visual check of the alignment of the interior components before assembly of the entire endoscope. Thus, the alignment of the

optical components can be tested and corrected without disassembly of a completed endoscope. II. Principles of Law Claim construction is the process by which courts determine the scope and

meaning of a patent’s claims. Markman v. Westview Instruments, Inc., 52 F.3d 967, 979 (Fed. Cir. 1995) (en banc), aff'd, 517 U.S. 370 (1996). “It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc).

Proper claim construction requires a court to review the patent's intrinsic evidence and, when appropriate, extrinsic evidence. See Id. at 1317. Courts typically give the words of a claim their “ordinary and customary meaning” as

understood by “a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Id. at 1312– 13. In construing a term, courts consider the context of what was actually invented and what the inventor intended the patent claims to cover. Renishaw PLC v.

Marposs Societa' per Azioni, 158 F.3d 1243, 1250 (Fed. Cir. 1998). Patent claims carry a presumption of validity. 35 U.S.C. § 282. So, courts must construe claims to preserve their validity, absent clear and convincing evidence of invalidity. Id.;

Dana Corp. v. Am. Axle & Mfg., Inc., 279 F.3d 1372, 1376 (Fed. Cir. 2002). “Claim construction begins with the language of the claims.” Kaneka Corp. v. Xiamen Kingdomway Group Co., 790 F.3d 1298, 1304 (Fed. Cir. 2015) (citing Phillips, 415 F.3d at 1312–14). Thus, claim construction begins, and sometimes

ends, with the consideration of intrinsic evidence—which consists of the patent claims themselves, the specification, and the patent’s prosecution history. Phillips, 415 F.3d at 1314–17. Claim terms must be reviewed in light of the intrinsic

evidence because a “person of ordinary skill in the art is deemed to read the claim term not only in the context of the particular claim in which the disputed term appears, but in the context of the entire patent, including the specification.” Id. at

1313. Overall, the focus of claim construction “must begin and remain centered on the language of the claims themselves” because that is the language that the patentee chose to specifically lay claim to the invention. Interactive Gift Exp., Inc.

v. Compuserve Inc., 256 F.3d 1323, 1331 (Fed. Cir. 2001). Patent specifications, which are governed by 35 U.S.C § 112, contain “a written description of the invention, and of the manner and process of making and using it.” 35 U.S.C. § 112. The written description “must be clear and complete

enough to enable those of ordinary skill in the art to make and use it.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). Section 112 requires that a patent “conclude with one or more claims particularly pointing out

and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.” 35 U.S.C. § 112.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Karl Storz Endoscopy-America Inc v. STERIS Instrument Management Services, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/karl-storz-endoscopy-america-inc-v-steris-instrument-management-services-alnd-2020.